AISAP Secures $13M Seed Funding for Rapid AI-Powered Ultrasounds Delivering Results in Minutes

In a significant advancement in medical imaging, Israeli startup AISAP has announced it has secured $13 million in seed funding for its innovative AI-driven software platform. This platform connects to standard ultrasound wands and sensors, enabling rapid assessment of patients’ conditions, even for physicians without formal training in ultrasound analysis.

AISAP’s Point-of-Care Assisted Diagnosis (POCAD) can deliver results in as little as five minutes, unlike traditional ultrasound procedures that can take hours or days due to reliance on radiologists and lab processing.

“The problem we’re addressing is that imaging is a scarce resource globally and there's insufficient availability,” said Roni Attali, AISAP CEO and a PhD in biotechnology, neurology, and organic chemistry, during a recent media interview.

The funding round was led by Harel Insurance Investments & Financial Services Ltd. and Shoni Health.

Founding and Mission

Founded by a diverse group of experts from the medical, technology, and intelligence fields, including Adiel Am-Shalom from the IDF’s elite 8200 Unit and Ehud Raanani, Director of the Leviev Cardiovascular and Thoracic Center at Sheba Medical Center, AISAP is focused initially on cardiac medicine with plans for broader applications.

“We aim to provide essential information swiftly after a five or six-minute scan, rather than the prolonged scans typical in echolabs,” said Robert Klempfner, AISAP co-founder and chief medical officer. “This efficiency allows physicians to make informed decisions promptly, whether that means obtaining more detailed images or intervening in emergencies.”

Delivering preliminary diagnoses faster than traditional methods could significantly impact patient outcomes, particularly for critical conditions involving the heart.

How AISAP’s POCAD System Works

The POCAD software, which is HIPAA compliant and ISO 13485 certified, operates in the cloud and can be deployed in hospitals or field settings. Importantly, it integrates with existing ultrasound equipment, eliminating the need for new machines.

“You don’t need to buy a new machine; hospitals already have what they need,” Attali emphasized.

Designed for ease of use, POCAD features an “urgency score” to prioritize care based on the severity of conditions, along with a quality score to ensure reliable diagnostics, even for less experienced operators. The underlying machine learning model was trained on 24 million echocardiogram video clips from over 300,000 studies from Sheba Medical Center.

“How can we harness the knowledge of our top cardiologists at Sheba, who have interpreted millions of cardiac images?” asked Klempfner. “Our goal is to equip non-cardiologists with critical information, even during off hours in emergency or critical care settings.”

POCAD operates on a software-as-a-service (SaaS) subscription model based on user numbers.

Compelling Initial Results

In a recent study conducted at Sheba Medical Center, POCAD was tested in emergency and internal medicine departments. Preliminary findings revealed that 29% of 660 patients, who had not undergone comprehensive ultrasounds, were found to have at least one previously undetected moderate medical condition.

Tamir Pardo, former head of Mossad and current leader of AISAP’s Strategic Board, highlighted the transformative potential of this technology: “The ability to provide critical diagnoses anywhere, anytime, without needing a dedicated expert represents a paradigm shift that could save countless lives.”

With its newly acquired funding and cutting-edge AI solution, AISAP aims to redefine medical diagnosis standards, making rapid, accurate ultrasound evaluations more accessible. POCAD is currently available in hospitals in Israel, with plans for a U.S. launch pending FDA approval.